Circulating Biomarkers for Cardiotoxicity Risk Prediction

Fei Fei Gong, Gregory J. Cascino, Gillian Murtagh, Nausheen Akhter*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Improvements in cancer survival have led to the emergence of cardiovascular disease as an important determinant of adverse outcome in survivors. Cancer therapeutics–related cardiac dysfunction is the most well-known form of cardiotoxicity. However, newer cancer therapies bring a broader range of cardiotoxicities. The optimal method to identify patients at risk of these complications is unclear, but circulating biomarkers comprise one possible approach. Troponins and natriuretic peptides have garnered the broadest evidence base for cardiotoxicity risk prediction, but other markers are being investigated. In this review, we explore evidence for circulating biomarkers in cardiotoxicity prediction associated with cancer therapies.

Original languageEnglish (US)
Article number46
JournalCurrent treatment options in oncology
Issue number6
StatePublished - Jun 2021


  • Biomarkers
  • Cancer therapy
  • Cardiotoxicity
  • Risk prediction

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Circulating Biomarkers for Cardiotoxicity Risk Prediction'. Together they form a unique fingerprint.

Cite this